CRISPR Therapeutics AG - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CRISPR Therapeutics AG on December 20, 2021, reporting an event that occurred on December 14, 2021. The company is incorporated in Switzerland and its common shares trade on The Nasdaq Global Market under the symbol CRSP.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the departure of a senior executive. On December 14, 2021, Tony W. Ho was terminated from his position as Executive Vice President, Research and Development. The filing states that the termination was without cause and was not the result of any disagreement with the Company.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors beyond the executive departure. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Executive Vice President, Research and Development, Tony W. Ho, was terminated on December 14, 2021.
- The termination was explicitly stated as being without cause.
- The company confirmed there was no disagreement between the executive and the company regarding the termination.
- The report was signed by Samarth Kulkarni, Ph.D., Chief Executive Officer.